Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2016

View Archived Issues

[11C]GSK-1482160: a PET radiotracer for imaging P2X7 receptors in neuroinflammation

Cell Medica and Baylor collaborate on next-generation cellular immunotherapies

Cancer Moonshot 2020 program forms the Melanoma and Sarcoma Working Group

Novartis initiates phase I/Ib study of LSZ-102 in ER-positive breast cancer

OxiGENE changes company name to Mateon Therapeutics

New rexinoid shows promise for the treatment of obesity and diabetes

Novira Therapeutics patents anti-HBV compounds

Array BioPharma and Celgene report JAK inhibitors

Intra-Cellular Therapies presents PDE2A inhibitors

Inovio Pharmaceuticals cleared to begin first phase I trial of Zika vaccine

Nivolumab evaluated for metastatic uterine leiomyosarcoma, colorectal cancer and ovarian cancer

Ipafricept plus carboplatin and paclitaxel well tolerated in phase Ib trial

FDA clears Sangamo BioSciences' IND for SB-913

EUROSTARS grant supports development of APO-010 for multiple myeloma

Afstyla available in U.S. for hemophilia A

Mitsubishi Tanabe Pharma submits NDA for edaravone for ALS

ApeX Therapeutics files IND for phase I trial of APX-3330 for pancreatic ductal adenocarcinoma

First-in-human results for the novel oral RAF inhibitor HM-95573

Takeda begins phase IIb trial for norovirus vaccine

New phase I trial studies UCART-19 in pediatric patients with B-ALL

Enanta starts phase I trial pan-genotypic cyclophilin inhibitor for HCV

FDA approves Rayaldee for secondary hyperparathyroidism in CKD

FDA approves use of Procleix Zika virus blood screening assay under IND study protocol

Inhibition of TGF-beta signaling to treat myelofibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...